When it comes to Bristol-Myers Squibb’s Celgene buyout, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. That support deals a blow to investor rebels fighting the merger. More: BMS-Celgene merger chances improve with backing
read moreOnly a month after making some senior-level changes, Daiichi Sankyo now figures it’s the right time to change its CEO as well. The company’s current president will take the helm and steer the company’s transition toward oncology, a move evident
read moreJohnson & Johnson’s anticoagulant Xarelto has picked up an industry first. On Friday, it became the subject of the first-ever TV drug ad with a list price included. More: Price checked: J&J launches industry-first TV ad with drug list price Source:
read moreNovo Nordisk this last week reached an agreement that will hold generic competition to its newer diabetes drugs for another five years. With that in the bag, it can now focus on next-generation products and so is investing nearly $100
read moreA key European regulatory committee backed Bluebird’s gene therapy to treat transfusion-dependent β-thalassemia, Zynteglo, setting up a possible EU approval in the second quarter—and renewing ongoing speculation about how the one-time treatment will be priced. More: Bluebird tees up its
read moreIf approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease. More: J&J submits sNDA for Invokana after premature end to clinical trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals